Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - Albiges, L; Gurney, H; Atduev, V (Lancet Oncol, 2023)
et al.